VRTX Vertex Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: VRTX

Price (delayed)

$468.42

Market cap

$118.89B

P/E Ratio

27.54

Dividend/share

N/A

EPS

$17.01

Enterprise value

$115.38B

?
Relative Growth: Rel. Growth: 93
Relative Strength: Rel. Strength: 50
Relative Valuation: Rel. Valuation: 63
Relative Profitability: Rel. Profitability: 99

Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather ...

Highlights
The equity has grown by 17% YoY and by 3.7% from the previous quarter
Vertex Pharmaceuticals's quick ratio has increased by 12% YoY and by 6% QoQ
The price to earnings (P/E) is 6% more than the 5-year quarterly average of 25.9 but 3.7% less than the last 4 quarters average of 28.6
VRTX's debt is up by 20% YoY and by 8% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: https://www.vrtx.com/
Peers: GILD ABBV MRK BMY

Key stats

What are the main financial stats of VRTX

VRTX stock price

How has the Vertex Pharmaceuticals stock price performed over time
Intraday
0.35%
1 week
3.37%
1 month
7.8%
1 year
5.61%
YTD
3.32%
QTD
4.9%

Financial performance

How have Vertex Pharmaceuticals's revenue and profit performed over time
Revenue
$12.22B
Gross profit
$10.54B
Operating income
$4.68B
Net income
$4.34B
Gross margin
86.2%
Net margin
35.5%
The operating income has grown by 12% since the previous quarter
The gross profit has grown by 10% YoY
VRTX's revenue is up by 10% YoY
Vertex Pharmaceuticals's net income has increased by 10% QoQ

Price vs fundamentals

How does VRTX's price correlate with its fundamentals

Growth

What is Vertex Pharmaceuticals's growth rate over time

Valuation

What is Vertex Pharmaceuticals stock price valuation
VRTX P/E details
P/E
27.54
P/B
6.15
P/S
9.74
EV/EBIT
22.29
EV/EBITDA
21.39
EV/Sales
9.44
The EPS has increased by 10% since the previous quarter
The price to earnings (P/E) is 6% more than the 5-year quarterly average of 25.9 but 3.7% less than the last 4 quarters average of 28.6
The equity has grown by 17% YoY and by 3.7% from the previous quarter
VRTX's revenue is up by 10% YoY
The price to sales (P/S) is 4.7% more than the 5-year quarterly average of 9.3 and 3.6% more than the last 4 quarters average of 9.4

Efficiency

How efficient is Vertex Pharmaceuticals business performance
The return on sales has increased by 9% since the previous quarter
VRTX's return on assets is up by 6% since the previous quarter
The return on invested capital rose by 6% since the previous quarter
The return on equity has grown by 5% since the previous quarter

Dividends

What is VRTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VRTX.

Financial health

How did Vertex Pharmaceuticals financials performed over time
Vertex Pharmaceuticals's total assets has increased by 16% YoY and by 3.3% QoQ
Vertex Pharmaceuticals's current ratio has increased by 14% YoY and by 4.1% from the previous quarter
VRTX's debt is 90% lower than its equity
VRTX's debt is up by 20% YoY and by 8% QoQ
The equity has grown by 17% YoY and by 3.7% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.